Go Ad-Free
    My Alerts
    Moneycontrol
    Moneycontrol PRO
    HomeNewsCipla

    Stock analysis is used by traders to make buy and sell call. It’s an approach to make informed decisions while investing in stocks. Stock analysis can be categorised into – fundamental analysis and technical analysis. Fundamental analysis is evaluation of data from sources, including financial records, economic reports, company assets, and market share. Analysts typically study the company’s financial statements – balance sheet, income statement, cash flow statement, and footnotes. These statements are made available to the investors in the form of quarterly earnings, disclosures to stock exchanges in compliance with the Securities and Exchange Board of India (Sebi) norms. In fundamental analysis, the analysts particularly check for a company's core income, income from other sources, profitability, guidance, assets and liabilities and debt ratio among other parameters. The other method, i.e. the technical analysis focuses purely on statistical data. It works on two assumptions; one, the stock price reflects the fundamentals. Second, the study of past and present movement in prices can help determine the future price trends. Technical analysis primarily deals with price, volume, demand and supply factors. This method is effective only when supply and demand forces influence the market. However, when outside factors are involved in a price movement, technical analysis may not be successful. More

    Jump to

    • Super Six stocks you can bet on November 16

      Sameet Chavan of Angel Broking advises buying State Bank of India with a target of Rs 258.

    • Hold Cipla, buy on dips: Deven Choksey

      Deven Choksey of KRChoksey Investment Managers recommends holding Cipla and advises buying the stock on dips.

    • Buy Cipla, advises Sudarshan Sukhani

      Sudarshan Sukhani of s2analytics.com is of the view that one can buy Cipla as the stock will rally.

    • Buy Cipla, Take Solutions, Ipca Laboratories: Kunal Bothra

      Kunal Bothra, Head of Advisory at LKP recommends buying Cipla, Take Solutions and Ipca Laboratories.

    • Cipla can head towards Rs 740: CA Rudramurthy BV

      CA Rudramurthy BV of Vachana Investments is of the view that Cipla can head towards levels of Rs 740.

    • Super Six intraday picks for the day

      Hemen Kapadia of KR Choksey Securities is of the view that one may buy Larsen and Toubro (L&T) with a target of Rs 1511.

    • Sell M&M, SAIL; buy Cipla: Sudarshan Sukhani

      Sudarshan Sukhani of s2analytics.com recommends selling Mahindra & Mahindra and Steel Authority of India and advises buying Cipla.

    • Buy Cipla 680 Call, should move higher: Amit Gupta

      Amit Gupta of ICICIdirect recommends buying Cipla 680 Call and feels that the stock should move higher.

    • Jai Bala positive on Cipla

      Jai Bala of 1857 Advisors is positive on Cipla.

    • Super Six short term picks for October 8

      Ashish Kyal of wavesstrategy.com is of the view that one may buy Godrej Properties with a target of Rs 365.

    • Super Six: Top chart picks for October 7

      Jay Thakkar of ShareKhan is of the view that one may buy EID Parry (India) with a target of Rs 147.

    • Positive on pharma, HUL top pick: Jai Bala

      Jai Bala of 1857 Advisors has a positive view on pharma stocks and has HUL as the top pick.

    • Stick to frontline pharma, barring Sun Pharma: Jai Bala

      Jai Bala of 1857 Advisors recommends sticking to frontline pharma names barring Sun Pharmaceutical Industries.

    • Super Six stocks you can give you handsome returns

      Meghana V Malkan of malkansview.com recommends selling Ashok Leyland with a target of Rs 84 and Just Dial with a target of Rs 934.

    • Strides Arcolab top pick, says Gautam Trivedi

      According to Gautam Trivedi, MD & CEO of Religare Capital Markets, Strides Arcolab is a top pick in the midcap pharma space.

    • Buy pharma stocks, advises Sudarshan Sukhani

      Sudarshan Sukhani of s2analytics.com recommends buying phrama stocks including Cipla and Dr Reddy's Laboratories.

    • Buy pharma stocks, says Sudarshan Sukhani

      Sudarshan Sukhani of s2analytics.com is of the view that pharmaceutical is an opportunity.

    • Super Six trading stocks for short term gain

      Hemen Kapadia of KRChoksey Securities suggests buying Cipla with a target of Rs 662.

    • Short Cipla, Hindustan Unilever: Amit Harchekar

      Amit Harchekar of A Plus Analytics recommends shorting Cipla as the stock can dip below Rs 620 and Hindustan Unilever with a target below Rs 730.

    • Is it the right time to enter pharma stocks?

      The pharma sector has seen the biggest correction over the past one month. The index itself has seen a 5 percent fall from the top. Abhishek Sharma, a pharma analyst at IIFL, gave his views on Dr Reddy's, Glenmark, Cipla and Sun Pharma.

    • Invest in ICICI Bank, Infosys, SBI, RIL, HUL: Sukhani

      Sudarshan Sukhani of s2analytics.com is of the view that ICICI Bank, Infosys, State Bank of India, Cipla, Dr Reddy's Laboratories, Hindustan Unilever and Reliance Industries are investment opportunities.

    • Prefer Cipla: Rajesh Kothari

      Rajesh Kothari - Managing Director at AlfAccurate Advisors is of the view that one may prefer Cipla.

    • Get in Cipla, says Gaurang Shah

      According to Gaurang Shah of Geojit BNP Paribas Financial Services, one may enter Cipla.

    • Top buzzing midcap stocks to trade on September 4

      Here are a few top buzzing midcap stocks picked by CNBC-TV18's analysts in trade today. We have - Cipla, Jyothy Laboratories, DLF, NIIT, VRL logistics, Ceat, Caplin Point Laboratories & Ujaas Energy.

    • Buy Cipla with view of atleast 2 years: Deven Choksey

      Deven Choksey of KR Choksey Investment Managers recommends buying Cipla with a view of two years or more.

    Advisory Alert: It has come to our attention that certain individuals are representing themselves as affiliates of Moneycontrol and soliciting funds on the false promise of assured returns on their investments. We wish to reiterate that Moneycontrol does not solicit funds from investors and neither does it promise any assured returns. In case you are approached by anyone making such claims, please write to us at grievanceofficer@nw18.com or call on 02268882347